Sanuwave Health reports 2026 reimbursement rates for UltraMIST® remain largely unchanged, aligned with CMS's final Physician Fee Schedule.
Quiver AI Summary
Sanuwave Health, Inc. announced that the final rule from the Centers for Medicare & Medicaid Services (CMS) for the 2026 Physician Fee Schedule maintains reimbursement rates for the CPT code 97610, used for UltraMIST® wound care products, that are largely unchanged from 2025. The rates for reimbursement in various care settings, including physician offices and hospitals, will remain within $2-4 of the previous year. This confirmation aligns with the company’s earlier expectations shared on October 6. CEO Morgan Frank noted that while some changes in wound care reimbursement exist, most providers will see a slight increase in rates for 2026. Sanuwave plans to address these updates in more detail during their third quarter earnings call.
Potential Positives
- The reimbursement rates for the UltraMIST® products under the 97610 code remain materially unchanged from 2025, providing stability for revenue expectations.
- The final rule aligns with the company’s prior expectations, demonstrating effective communication and management of stakeholder inquiries regarding reimbursement rates.
- Some providers may experience a slight increase in reimbursement, potentially enhancing the attractiveness of UltraMIST® treatment options.
- The press release signals a proactive approach by the company to keep investors informed, which may strengthen investor confidence and support.
Potential Negatives
- Reimbursement rates for UltraMIST® products remain materially unchanged, which may indicate limited growth potential in revenue amid evolving market conditions.
- The focus on reimbursement questions suggests a heavy reliance on specific CPT codes, potentially exposing the company to financial risk if future changes occur.
- The forward-looking statements caution investors about significant risks and uncertainties, which may undermine confidence in the company's future performance.
FAQ
What is the 2026 Physician Fee Schedule from CMS?
The 2026 Physician Fee Schedule outlines reimbursement rates for various CPT codes, including those for wound care treatments.
How does the final rule impact UltraMIST® reimbursement rates?
The reimbursement for the 97610 code for UltraMIST® remains materially unchanged, with rates within $2-4 of 2025 levels.
What changes can we expect in 2026 reimbursement rates?
Expected changes for 2026 are less than 1%, with some providers anticipating a slight increase in reimbursement rates.
When will Sanuwave discuss the reimbursement updates?
Sanuwave plans to discuss reimbursement updates further during their third quarter earnings call.
What should investors know about the forward-looking statements?
Investors should be aware that forward-looking statements involve risks and uncertainties and are not guarantees of future performance.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SNWV Insider Trading Activity
$SNWV insiders have traded $SNWV stock on the open market 3 times in the past 6 months. Of those trades, 1 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $SNWV stock by insiders over the last 6 months:
- IULIAN CIOANTA (Chief Sci. and Tech. Officer) sold 3,639 shares for an estimated $114,992
- PETER STEGAGNO (Chief Operating Officer) sold 1,862 shares for an estimated $51,596
- MANAGEMENT INC. OPALEYE purchased 1,267 shares for an estimated $38,360
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SNWV Hedge Fund Activity
We have seen 0 institutional investors add shares of $SNWV stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMALGAMATED BANK added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SNWV Analyst Ratings
Wall Street analysts have issued reports on $SNWV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Northland Capital Markets issued a "Outperform" rating on 09/03/2025
- Roth Capital issued a "Buy" rating on 08/22/2025
To track analyst ratings and price targets for $SNWV, check out Quiver Quantitative's $SNWV forecast page.
$SNWV Price Targets
Multiple analysts have issued price targets for $SNWV recently. We have seen 2 analysts offer price targets for $SNWV in the last 6 months, with a median target of $55.0.
Here are some recent targets:
- Carl Byrnes from Northland Capital Markets set a target price of $55.0 on 09/03/2025
- Kyle Bauser from Roth Capital set a target price of $55.0 on 08/22/2025
Full Release
CMS adopts Final Rule for 2026 Physician Fee Schedule in line with proposed rule for CPT code 97610
2026 rates for physician offices, home visits, long-term care, and hospitals are in line with the proposed rule and remain materially unchanged from 2025
EDEN PRAIRIE, Minn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today provided a business update regarding the anticipated impact of the final rule from the Centers for Medicare & Medicaid Services (“CMS”) for the 2026 Physician Fee Schedule, which were published after the close of business on Friday, October 31, 2025. This schedule established reimbursement rates for CPT codes for the coming calendar year.
Reimbursement for the 97610 code for UltraMIST ® products remains materially unchanged for 2026 with payment for treatment provided in the physician office, home visit, long-term care, and hospital settings remaining within $2-4 of 2025 rates. This is in line with the expectations the Company expressed in its preliminary revenue results release on October 6 th .
“In light of some changes on other wound care reimbursement, and in response to numerous inquiries from investors and providers about UltraMIST
®
reimbursement rates for 2026, we wanted to provide this informational update,” said Sanuwave CEO Morgan Frank. “Final 2026 rates for 97610 are in line with the proposed rule and with our prior expectations. Changes for 2026 should be less than 1% with many providers seeing a slight increase in reimbursement. We look forward to discussing this further on our third quarter earnings call.”
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to expected reimbursement levels for the UltraMIST procedure, future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.
Contact: [email protected]
